ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...

Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy.

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from...

Health for Life Capital is the only non-American investor alongside prestigious strategic and financial investors.

Within thirty months of its creation, MaaT Pharma, a European MicrobioTech1 specialized in the development of innovative treatments based on intestinal microbiota in...

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners...

Paris, France – July 5, 2017 - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector,...

Rapidly advancing understanding of the relationship between humans
and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to...